Health Insurance Fund (NEAK)

Hospital DRG/HBCS activity funding — the dominant clinical care line at 974,642 mFt, financing hospital inpatient and day-procedure activity through a diagnostic-related group tariff system. Hungarian hospitals had accumulated 300 million EUR in past-due debt by March 2024; the hospital association stated there is 'hardly any medical intervention for which funding provides sufficient coverage.' DRG tariffs set below cost-recovery create a soft budget constraint: hospitals overspend, the state bails out the debt, and the incentive to control costs disappears. The 7-year transition introduces managed competition among accredited providers.

Hospital inpatient services — 762,602 mFt, the largest single clinical expenditure in the entire Hungarian budget. Past-due hospital debt reached 300 million EUR by March 2024, rising at 3.7 billion Ft per month, because tariffs do not cover costs. The Kornai soft budget constraint diagnosis is exact: hospitals overspend because they expect (correctly) to be bailed out. The 7-year transition to managed competition — accredited hospitals negotiating tariffs with competing insurers — hardens the budget constraint by making insolvency possible and by aligning payment with delivered cost.

GYED and adoption benefit — earnings-based childcare benefit at 70% of prior wage for up to two years, financed from the health fund. Like CSED, the financing vehicle creates distorted incentives: the cost falls on the collective fund, not on individual employers, severing any actuarial link between workforce parental plans and employer cost. The 5-year phase-out transitions the benefit to a parental insurance model where individual employer contributions over the career period fund the benefit — Norway's model. No reduction in individual benefit levels for current or future recipients.

Pharmaceutical reimbursement — 434,423 mFt covering NEAK's contribution to the retail price of reimbursed medicines prescribed by Hungarian physicians. Hungary's pricing uses a reference-pricing system capped at the EEA average for the same product. The 5-year phase-out transitions to Medisave-equivalent health savings accounts funded by the 3% in-kind health contribution, with means-tested top-ups for patients whose accounts cannot cover their annual drug costs. Universal access to all clinically approved medicines is maintained through the means-tested floor.

Disability and rehabilitation benefits at 419,852 mFt — periodic income replacement for workers with assessed permanent disability. These are social-insurance claims against the health fund for those unable to work. The FSI's 7-year phase-out transfers this function to a separate disability insurance vehicle with actuarially sound employer liability contributions — the Dutch WIA model, where employer premiums reflect industry-specific disability incidence rates, creating incentive for workplace safety investment. Current recipients are grandfathered; no reduction in ongoing payments.

GP services and out-of-hours primary care — 296,534 mFt for a system with 3.03% of adult and 14.27% of mixed districts vacant at last count, concentrated in settlements under 5,000 inhabitants. The phase-out transitions the financing model: GPs become independent practitioners billing NEAK (or a successor insurer) per consultation, with a capitation supplement for rural accessibility. Sweden's 2010 mandatory nationwide primary care reform increased PHC centres by 26% in three years and raised private ownership from 30% to 44%. The function is kept; the financing architecture changes.

Sickness benefit (Táppénz) — 60–70% wage replacement during illness, funded from the health insurance pool rather than from experience-rated employer liability. Public-choice theory predicts exactly the outcome that Hungarian data shows: when sick-leave costs are socialised, individual employers have no incentive to invest in reducing incidence. The 5-year phase-out migrates to mandatory employer-funded sickness insurance for the first 15 working days (German model), with NEAK covering extended illness. Small firms with fewer than ten employees receive a transitional NEAK subsidy.

Outpatient specialist care — 221,118 mFt for consultations, diagnostics, and treatment by specialists in outpatient settings. Hungary's outpatient specialist system is characterised by long wait times and pervasive informal gratuity payments, indicating that official tariffs undervalue the service and that willingness-to-pay exceeds the administrative price. The 7-year phase-out transitions to competitive NEAK contracting with accredited specialist practices, including private clinics, with income-linked copayments at the point of use to manage demand.

High-cost medicine financing — 195,000 mFt for oncology biologics, rare disease treatments, and other innovations above the standard reimbursement threshold. The 5-year phase-out transitions to managed entry agreements (MEAs) with manufacturers — time-limited, outcome-conditional contracts where NEAK reimburses at full price only if treatment outcomes meet pre-agreed clinical benchmarks. Baker McKenzie notes Hungary recently reformed its pricing rules to allow market entry without prior multi-country reimbursement; the FSI endorses this direction and extends it to outcome-based payment design.

Infant care benefit (CSED) — 70% wage replacement for the first 24 weeks after birth, financed from the health insurance fund rather than employer liability insurance. The financing vehicle is the problem: pooling all employers' maternity costs severs the actuarial link between workforce composition and cost, removing employer incentive to invest in parental-return management. Individual benefit levels are unchanged; the 5-year phase-out transfers liability to mandatory employer short-term disability insurance (German Entgeltersatzleistung model) with a small-employer carve-out and NEAK subsidy for self-employed.

Pharmaceutical reimbursement reserve — 132,439 mFt held as a contingency for demand overruns in the main reimbursement budget. This reserve exists because pharmaceutical reimbursement under an open-ended universal system is inherently unpredictable: new drugs are approved mid-year, utilisation varies with disease incidence. Under a Medisave model with individual accounts, the reserve becomes unnecessary — individual accounts provide the shock absorber that the collective reserve currently must fund. The 5-year phase-out tracks the pharmaceutical reimbursement transition timeline.

Dental care — 86,612 mFt for a service where private-market provision is already dominant: most Hungarians either pay out-of-pocket for private dentistry or access the NEAK-funded system with pervasive informal gratuity payments to supplement below-cost tariffs. The 5-year phase-out withdraws NEAK financing for working-age adults with above-median incomes and replaces it with a means-tested dental benefit for low-income adults and universal child dental care. This mirrors the NHS Wales model: universal child dental access, income-tested adult access, market provision for those above the threshold.

Supplementary provider financing — an 80,000 mFt hospital debt patch covering past-due liabilities that HBCS tariffs cannot service. This line is the most direct evidence of the soft budget constraint: hospitals accumulate debt at 3.7 billion Ft per month (2023 NEAK data), and the state appropriates a separate patch to cover part of the accumulated liability. The 3-year phase-out is conditional on the DRG tariff reform (LXXII-E7-7): only when tariffs cover costs does the structural debt accumulation stop and this patch become unnecessary. Patching without reforming perpetuates the cycle.

Specially financed specialist care — 74,383 mFt for high-complexity specialist treatments outside the standard DRG framework. These include organ transplant programmes, complex oncology protocols, and tertiary interventions that require separate pricing because their clinical heterogeneity prevents standard DRG grouping. The 7-year phase-out transitions these services to negotiated value-based contracts (outcome-linked payment) with specialist centres — the NHS England specialised commissioning model. Universal access for all clinically indicated patients is maintained throughout.

Medical device reimbursement and lending — 64,558 mFt for NEAK-funded prosthetics, orthotics, wheelchairs, hearing aids, and other medical devices. This is a population with genuine unmet need and limited private-market alternatives for lower-income patients. The 5-year phase-out transitions to a voucher system where eligible patients receive a device credit redeemable at any accredited provider, creating competition among device suppliers and eliminating the current single-source public procurement model that generates quality-constraining monopoly contracts.

Ambulance and emergency rescue — 45,782 mFt for the OMSZ (Országos Mentőszolgálat) national ambulance service. Emergency medical response is a clear public-good case: the service cannot be priced at point of use (a patient in cardiac arrest cannot negotiate a fee), response time depends on universal network coverage rather than individual demand, and private markets have not produced adequate emergency ambulance coverage in any comparable country. The FSI keeps this line unconditionally. This is the constitutional minimum for health infrastructure.

Dialysis — 38,771 mFt for renal replacement therapy in accredited dialysis centres. This is among the clearest cases in the health fund for preserved public financing: dialysis is life-sustaining treatment for approximately 6,000–8,000 patients; the frequency (three times per week) and cost create uninsurable individual exposure; and private insurance markets do not cover existing chronic renal failure. The 7-year phase-out category reflects transition to a capitated chronic disease management model, not elimination of coverage. All current and future dialysis patients retain full NEAK financing.

Laboratory diagnostic services — 30,296 mFt for NEAK-contracted laboratory testing. Laboratory diagnostics are among the most contestable healthcare services: capital requirements are high but not prohibitive for private operators, quality can be objectively measured through accreditation standards, and competitive tendering of laboratory contracts has produced significant cost reductions in comparable markets (NHS England's pathology consolidation, 2016–2019). The 5-year phase-out transitions to competitive NEAK contracting with accredited laboratories — public and private — with uniform per-test tariffs.

Health visitor services (védőnők) and maternal/child health protection — public health nurses visiting pregnant women, newborns, and young children. Early identification of developmental delays and parental stress prevents far more expensive acute interventions. The 7-year phase-out transitions funding from the health insurance pool to a dedicated public health budget, preserving the function while removing it from actuarial insurance where it structurally does not belong.

Emergency care for foreign nationals under treaty obligations — 27,039 mFt covering treatment costs for EU citizens presenting EHIC cards and visitors from bilateral agreement countries. These are treaty obligations under EU Regulation 883/2004 and bilateral social security agreements; no discretionary element exists. The FSI keeps this line. Refusing emergency treatment to EHIC cardholders would breach EU law and create immediate Commission infringement proceedings. The relevant reform is improving EHIC cost-recovery from partner country insurers to ensure Hungary is fully reimbursed for cross-border care costs.

Custom orthotics reimbursement — 16,967 mFt for individually-fabricated medical devices (braces, prostheses, custom insoles) requiring patient-specific manufacturing. The 5-year phase-out transitions to means-tested vouchers: patients receive a credit covering the cost of a standard approved device, with the option to top up from personal funds for premium specifications. This is the Medisave-compatible model — the standard device cost is covered from health savings plus top-up option; the means-tested floor covers the standard device for patients who cannot afford top-ups.

Home nursing (Otthoni szakápolás) — professional nursing visits for patients recovering at home following hospital discharge or managing chronic conditions. This is a genuinely cost-effective service: home nursing delays or prevents more expensive hospital readmissions. The 5-year phase-out transitions the financing from NEAK to a dedicated long-term care budget that also covers residential and community care, ensuring continuity of service delivery. The function is preserved; the financing vehicle changes to reflect the non-acute nature of the service.

Patient transport — ambulances and medical vehicles for non-emergency patient transfer between care facilities and from home to treatment sites. The 5-year phase-out transitions non-emergency patient transport to a regulated concession model where competitive operators bid for NEAK-contracted routes, preserving universal access while reducing costs through competition. Emergency transport (LXXII-E7-8) is kept as a directly-funded public service; planned non-emergency transport is a different function that does not require state monopoly provision.

Compensation and accident annuities — periodic payments to workers with work-related permanent incapacity, established by court judgment. These are civil liability claims against the fund arising from historical employer or state responsibility determinations. The FSI keeps all existing annuities in full; the 7-year classification reflects natural cohort wind-down. No new annuities enter the health fund; future work-related disability claims belong in a mandatory employer liability insurance framework.

Molecular diagnostic (PCR) services — 10,802 mFt for state-funded PCR testing capacity retained after the COVID-19 pandemic. This capacity was scaled for pandemic conditions and is now oversized for routine clinical use. The 5-year phase-out transitions PCR and molecular diagnostic services to the general laboratory contracting framework (LXXII-E7-9), where competitive tendering reduces per-test cost. Emergency pandemic testing capacity is maintained under a public health contingency reserve funded from general health emergency provisions.

NEAK central administration — 8,883 mFt for personnel, material, and capital costs of the national health insurance fund manager. NEAK's administrative role diminishes as managed competition transfers contracting functions to competing insurers; the 5-year phase-out tracks this institutional transition. The Slovak Republic's 2003–2004 managed competition reform transformed public health insurance funds into joint-stock insurance companies — a direct precedent for Hungary. NEAK's successor entities are insurers, not a central fund manager; their administrative costs are funded from premiums, not from the central budget.

Pharmacy dispensing fee — 8,800 mFt paid by NEAK to pharmacies for the professional dispensing service on reimbursed prescriptions. A nominal freeze is appropriate: the dispensing fee compensates a genuine professional service (medication counselling, contraindication checking, dosage guidance) that has public health value. As pharmaceutical reimbursement transitions to a Medisave model, the dispensing fee structure would migrate to a per-prescription fee paid from the patient's health-savings account rather than from NEAK — the function is preserved, the payment vehicle changes.

Curative-preventive care reserve — 7,460 mFt held as a contingency within the clinical care block for mid-year demand fluctuations. Under managed competition, this function is absorbed by individual insurer risk reserves; collective NEAK contingency reserves become redundant. The 7-year phase-out tracks the DRG and managed-competition transition timeline. As NEAK's direct provider-financing role diminishes, its need to hold clinical contingency reserves diminishes in proportion.

Employer administration fee for sickness benefit disbursement — NEAK reimbursing employers for the administrative cost of processing táppénz payments. A nominal freeze is appropriate: this line is proportional to táppénz volume and will contract as the táppénz phase-out progresses. Once the employer-funded first-15-days model is established, the administration fee structure inverts: NEAK pays employers for the extended-illness cases it still funds, not for the employer-funded first-period cases.

Patient travel reimbursement — 6,161 mFt covering transport costs for patients who must travel to specialist centres for treatment. A nominal freeze is appropriate for a genuine access instrument: rural and mobility-constrained patients face real barriers to reaching specialist care, and travel reimbursement partially mitigates this. The FSI prefers transition to a means-tested travel voucher model rather than universal reimbursement — patients who can afford travel costs should pay them, while those who cannot receive the voucher. The nominal freeze preserves real-value erosion while the means-test design is developed.

Postal costs for cash benefit disbursement — 5,005 mFt for mailing benefit payments to recipients without bank accounts. A nominal freeze creates fiscal pressure to accelerate electronic payment migration. Hungary's banking penetration for adults aged 18+ is approximately 90%; the remaining postal recipients are disproportionately elderly and rural. A targeted outreach programme (free basic payment accounts for benefit recipients, as implemented in Germany under Basiskonto regulation) would accelerate the transition without excluding the most vulnerable recipients.

Additional capacity admission funding — 4,000 mFt covering the cost of expanding NEAK's registered capacity for specific services where demand exceeds supply. The 7-year phase-out reflects the transition to a managed-competition model where capacity expands in response to insurer contracts rather than administrative admission decisions. Under managed competition, insurers pay for capacity utilised; supply responds to demand signals. Administrative capacity allocation — the function this line funds — becomes redundant.

Special overseas healthcare — 3,220 mFt for highly specialised treatments not available in Hungary where NEAK pre-authorises treatment abroad. The 5-year phase-out transitions to direct contracting between Hungarian insurers and European specialist centres — the Swiss model, where Swiss cantonal hospitals have direct contracts with German and French university hospitals for highly specialised procedures. Pre-authorisation is preserved; the financing vehicle changes from a central NEAK line to insurer-managed cross-border contracts.

In-kind benefits reserve — a 3,000 mFt contingency within the clinical benefits block. The FSI keeps this at its current level: a small contingency reserve within a 4.9 trillion Ft fund is operationally justified for mid-year demand fluctuations on discrete in-kind items (specific devices, one-off clinical innovations). Under managed competition this function would be absorbed by insurer risk reserves; the transition period warrants maintaining a modest NEAK contingency.

Public health development — 2,718 mFt for preventive health programmes, health promotion, and population-level disease prevention initiatives. Public health interventions exhibit genuine public-good characteristics: a vaccination campaign or smoking cessation programme benefits the whole population beyond the direct participants. The FSI applies a phase-out classification because this function belongs in a dedicated public health budget rather than the acute care insurance fund. The function is preserved; the financing vehicle changes.

Spa and balneological therapy subsidies — 2,514 mFt for NEAK-reimbursed thermal and rehabilitation treatments at accredited facilities. The clinical evidence base for balneological treatments is mixed outside specific musculoskeletal indications; the subsidy has a public-choice flavour (Hungary's thermal spa industry benefits from prescribed medical tourism at public expense). A nominal freeze is appropriate: the amount is small, some clinical applications are genuine, and the FSI's preferred reform is a narrower clinical indication list rather than elimination.

Operating cost advances — 2,000 mFt in pre-payments to providers to cover cash-flow shortfalls ahead of monthly NEAK tariff receipts. This line exists because NEAK tariffs are set below cost-recovery, creating structural cash-flow deficits that require prepayments. The 7-year phase-out is consequential of the DRG reform: when tariffs are set at actual cost-recovery levels through managed competition, providers no longer need operating cost advances. Eliminating the symptom (prepayments) without addressing the cause (below-cost tariffs) would simply accelerate hospital insolvency.

Extra-tariff financing — 1,000 mFt for services billed above the standard HBCS tariff in exceptional clinical circumstances. The 7-year phase-out reflects the disappearance of this line under managed competition: if tariffs are negotiated at cost-recovery levels, extra-tariff supplements are unnecessary. Their existence is a symptom of inadequate base tariffs, not an independent service category. When the base tariff reform completes, extra-tariff supplements have no residual function.

Lump-sum hardship assistance — a residual discretionary payment with no clear eligibility criterion visible at the budget aggregation level. At 450 mFt this is small; the absence of stated criteria is the governance concern. Any genuine hardship function should be absorbed into the means-tested social assistance framework in Chapter XLII, where eligibility standards are defined. The 3-year phase-out allows existing ad-hoc commitments to run off while the function is transferred to the social assistance chapter.

Miscellaneous administrative expenditures of the Health Fund — a residual catch-all at 235 mFt. A nominal freeze is appropriate for any unitemised administrative residual. At this size, the governance requirement is sub-itemisation in the supplementary tables rather than independent reform. Transparent classification — which costs are IT, which are legal, which are external advisory — enables meaningful benchmarking against comparable health fund administrators.

Human milk supply — 200 mFt for the national milk bank providing pasteurised donor breast milk for premature neonates. This is a neonatal intensive care function with clear clinical necessity, no viable market substitute, and a small, bounded beneficiary population. The FSI keeps this line unconditionally. At 200 mFt the cost is trivial relative to the neonatal intensive care episode it supports; no reform argument applies.

Planned overseas treatment reimbursement — 106 mFt covering cases where Hungarian patients travel abroad for planned treatments under EU patient mobility rights (Directive 2011/24/EU). The 5-year phase-out is not about denying patient rights — it is about ensuring that planned overseas treatment is funded through the insurer framework (NEAK successor insurers contract with European hospitals) rather than through a central NEAK reimbursement line. Under managed competition, insurers contract cross-border care directly; this central reimbursement becomes redundant.

Asset management expenditure of the Health Fund — at 5.7 mFt, this is trivially small because NEAK holds no significant reserves by design in a pay-as-you-go health insurance architecture. The line will grow as health-savings accounts accumulate balances under the Medisave transition — investment management costs are inherent in any funded savings model. A nominal freeze is appropriate now; the function and its costs will be redesigned when the Medisave framework is established.